GT Biopharma, Inc.
NASDAQ Capital MarketTotal Valuation
GT Biopharma, Inc. carries a market capitalization of 7.60M, placing it among publicly traded companies globally. Its enterprise value stands at 5.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.60M |
| Enterprise Value | 5.44M |
Share Statistics
GT Biopharma, Inc. currently has 35.18M shares outstanding.
| Shares Outstanding | 35.18M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.89 |
| P/TBV Ratio | 1.89 |
| P/FCF Ratio | -0.38 |
| P/OCF Ratio | -0.38 |
Financial Position
GT Biopharma, Inc. maintains a current ratio of 4.14, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.14 |
| Quick Ratio | 3.69 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -211.71 |
Financial Efficiency
| Return on Equity (ROE) | -1,959.62 |
| Return on Assets (ROA) | -754.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -1,036.73 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
GT Biopharma, Inc.'s stock has declined approximately -74.05813% over the past 52 weeks. The 50-day moving average sits at 0.35, while the 200-day moving average is 0.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | -74.05813% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.48 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.34M, while operating income came in at -13.34M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.34M |
| Pretax Income | -47.73M |
| Net Income | -47.73M |
| EBITDA | -13.34M |
| EBIT | -13.34M |
| Earnings Per Share (EPS) | -3.87 |
Balance Sheet
Total book value stands at 7.58M, with working capital of 7.58M providing operational flexibility.
| Cash & Cash Equivalents | 8.92M |
| Total Debt | N/A |
| Net Debt | -8.92M |
| Equity (Book Value) | 7.58M |
| Book Value Per Share | 0.22 |
| Working Capital | 7.58M |
Cash Flow
GT Biopharma, Inc. produced -13.18M in operating cash flow over the past twelve months.
| Operating Cash Flow | -13.18M |
| Capital Expenditures | N/A |
| Free Cash Flow | -13.18M |
| FCF Per Share | -1.07 |
Dividends & Yields
The company's payout ratio of 0.58 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.01 |
| Dividend Yield | N/A |
| Payout Ratio | 0.58 |
| Shareholder Yield | -137.48 |
| FCF Yield | -261.89 |
Stock Splits
GT Biopharma, Inc.'s most recent stock split took place on February 5, 2024 with a 30:1 split ratio.
| Last Split Date | 2/5/2024 |
| Split Ratio | 30:1 |
Scores
GT Biopharma, Inc. posts an Altman Z-Score of -101.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -101.73 |